iiinova — where your digital self keeps evolving

Philippe Aftimos, MD @aftimosp.bsky.social · 22/09/2026

With #ESMO26 in Madrid around the corner, the LBAs list os now available online and in the program! #ESMOAmbassadors

Philippe Aftimos, MD @aftimosp.bsky.social · 18/09/2026

I am thrilled to be part of this group with stellar ⭐️ colleagues and I look forward to interactions and discussions around high quality data at #ESMO26 ! #ESMOAmbassadors

011

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 12/03/2026

In #RareCancers, guidelines are vital to bring together scattered expertise. A recent EURACAN survey highlights a high uptake of recommendations from oncologists, potentially leading to improved patients’ survival. #ESMORareCancers26 #ESMODailyReporter 📌 ow.ly/nooJ50YsIQ9

054

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 06/03/2026

Do you have an impactful research idea? One that could improve care or advance science? Apply for the ESMO Leadership & Career Development Award, offering protected research time, leadership & communication training by 3 May 26 . 🔗https://ow.ly/Gicm50YqcbZ #Oncology #ESMOYOC

156

Philippe Aftimos, MD @aftimosp.bsky.social · 24/01/2026

Spiderweb 🕸️ is a decentralised clinical trials initiative by the Oncodistinct network. Learn more in this commentary by Nuria Kotecki and Simon Nannini ascopubs.org/doi/10.1200/...

ascopubs.org

Innovative Research Organization to Facilitate Clinical Trials Implementation in the Era of Molecular Oncology: The Spiderweb Model of the Oncodistinct Network | JCO Precision Oncology

010

Philippe Aftimos, MD @aftimosp.bsky.social · 06/01/2026

January 16 & 17, 2026 - Brussels Two days packed with top expertise, debate, and insights from the past year in breast cancer care. Institut Jules Bordet & UZ Leuven invite you to this annual double meeting, which has become a fixture Registration link ✍️👇 accredimix.be/debate-highl...

031

Philippe Aftimos, MD @aftimosp.bsky.social · 12/07/2025

Rotterdam citytrip and Union Saint-Gilloise 💛💙 at De Kuip 🚂☀️🚤🏟️

130

Philippe Aftimos, MD @aftimosp.bsky.social · 08/07/2025

I am a big fan of @fontainesdc.bsky.social and I discovered their partnership with @bfcdublin.bsky.social at Rock Werchter. I immediately loved the club’s vibes. And that third jersey, wow 🤩

020

Philippe Aftimos, MD @aftimosp.bsky.social · 16/06/2025

I reviewed for @myesmo.bsky.social new data with a potential clinical impact in HR+/HER2- metastatic breast cancer 👇

010

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 28/05/2025

#ESMOMembers – vote for the leaders who will shape ESMO’s future. Vote now for the Directors of Education, Public Policy & Membership - and the Chair and members of the Nomination Committee. 📽️ Watch the ESMO President’s message 🔗 Vote now: ow.ly/H7UK50VZR0X

051

Philippe Aftimos, MD @aftimosp.bsky.social · 24/05/2025

Cool simultaneous illustration of my talk at the seminar series organised by Institut Jules Bordet to celebrate Clinical Trials Day

000

Philippe Aftimos, MD @aftimosp.bsky.social · 17/05/2025

🇩🇪 🚆 🇧🇪 🚌 🏟️ ⚽️💛💙

110

Reposted by Philippe Aftimos, MD

Laurence Buisseret @laubdh.bsky.social · 16/05/2025

@hoperugo.bsky.social is discussing the results of the ROSALINE trial, an IIT sponsored by the Institut Jules Bordet that evaluated ROS1 inhibition with neo-adj endocrine therapy in early ILBC #ESMOBreast25 👏🏻 @aftimosp.bsky.social & Soraia Lobo-Martins

021

Philippe Aftimos, MD @aftimosp.bsky.social · 15/05/2025

Day 2 of #ESMOBreast25 in Munich. Data on ADCs will be presented during Mini Oral session 1 including results on 2️⃣ novel ADCs targeting B7H4 in HR+/HER2- and TNBC: emiltatug ledadotin and puxitatug samrotecan #ESMOAmbassadors @myesmo.bsky.social

082

Philippe Aftimos, MD @aftimosp.bsky.social · 14/05/2025

Part of the Institut Jules Bordet breast cancer team at #ESMOBreast25 @laubdh.bsky.social

151

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 14/05/2025

In her Keynote Lecture at #ESMOBreast25, @loisher.bsky.social considers the question of who truly benefits from #immunotherapy in #BreastCancer, noting that success hinges on careful definition of responsive patient subgroups. Full article in the #ESMODailyReporter 🔗 ow.ly/rtbo50VSyiN

042

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 14/05/2025

#ESMOBreast25 Award recipient, Gabriel Hortobagyi, describes the long journey that has led to targeted #BreastCancer therapies and explains how patient involvement is central to advancing research. Read more in the #ESMODailyReporter 🔗 ow.ly/kqju50VSpOE

051

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 14/05/2025

At #ESMOBreast25, refinements in #LiquidBiopsy use are reviewed, including a defined window for ESR1 mutation detection in metastatic #BreastCancer and use of pre-neoadjuvant treatment #ctDNA levels to predict recurrence. More in the #ESMODailyReporter 🔗 ow.ly/R93050VSChg

042

Philippe Aftimos, MD @aftimosp.bsky.social · 14/05/2025

An enthusiast and militant talk by @marleenkok.bsky.social at #ESMOBreast25 on the importance of studying biomarkers for immunotherapy in breast cancer, highlighting the KN522 example #ESMOAmbassadors @myesmo.bsky.social

173

Philippe Aftimos, MD @aftimosp.bsky.social · 14/05/2025

#ESMOBreast25 @laubdh.bsky.social from Institut Jules Bordet on the role of immunotherapy in ER+/HER2- early breast cancer #ESMOAmbassadors @myesmo.bsky.social

062

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 12/05/2025

#ESMOBreast25: Do not miss the latest research findings in #BreastCancer brought to you by the #ESMOAmbassadors & become part of the conversation. #bcsm 🔗 ow.ly/VtAE50VP4Jf

164

Philippe Aftimos, MD @aftimosp.bsky.social · 01/05/2025

Floralia Brussels 2025 🌷 floralia-brussels.be/en

110

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 01/04/2025

🚀 ESMO is now on Bluesky This is not an April Fools' announcement, nor is it an AI-generated post. ESMO is launching on Bluesky with a poll on AI to start the conversation. Join us for the latest in oncology education and information. #AIOncology #HealthAI #ESMOAI25

32410

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 07/04/2025

Newly published ESMO recommendations provide roadmap for the implementation of molecular tumour boards in clinical practice. Discover the key focus areas to optimise #PrecisionOncology Read via #ESMODailyReporter: ow.ly/uQGA50Vvu4j @benwestphalen.bsky.social

174

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 10/04/2025

📣#ESMOBreast25: Regular abstract titles and authors are online! Check the programme to see the exciting studies you will have the chance to see at this event. ⏰And if you register by 17 April, you can benefit from advantageous rates! 🔗 buff.ly/9Ply77K

042

Philippe Aftimos, MD @aftimosp.bsky.social · 10/04/2025

So many interesting discussions with very bright 💡 people!

010

Reposted by Philippe Aftimos, MD

Antonio Mulero @amuleros.bsky.social · 04/04/2025

What an outstanding summit organized by SOLTI. Key overview on the Lobular BC: current clinical research, pathological characterization and imaging and focus on big alliances to move forward on the field. #uptodatesummit #beSOLTI

121

Philippe Aftimos, MD @aftimosp.bsky.social · 29/03/2025

L’Union n’a pas besoin d’être champion (mais on le sera)

120

Reposted by Philippe Aftimos, MD

Julien Tlx @citizenjulien.bsky.social · 29/03/2025

J'ai signé. Et toi ?

073

Philippe Aftimos, MD @aftimosp.bsky.social · 21/03/2025

The United Nations World Water Development Report 2025, Mountains and glaciers: water towers unesdoc.unesco.org/notice?id=p:...

unesdoc.unesco.org

000

Philippe Aftimos, MD @aftimosp.bsky.social · 11/03/2025

Now available in NPJ Precision Oncology, results from the BALLETT molecular profiling study 🧬 🎯 using CGP & a national 🇧🇪 molecular tumor board. BALLETT is part of the @mybsmo PRECISION program. 👏 Brigitte Maes & Pieter-Jan Volders www.nature.com/articles/s41...

nature.com

A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer - npj Precision Oncology

npj Precision Oncology - A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer

020

Reposted by Philippe Aftimos, MD

European Lobular Breast Cancer Consortium @elbcc-2018.bsky.social · 27/02/2025

We have overhauled www.elbcc.org and ask all existing and future participants to register and indicate their preferred working groups. Check the site, current members, and spread the word! @christinedesmedt.bsky.social @pwbderksen.bsky.social @lobularbcuk.bsky.social @lobularbca.bsky.social

058

Philippe Aftimos, MD @aftimosp.bsky.social · 16/02/2025

🎶 🐈 youtu.be/bFa8FL5wG10?...

020

Philippe Aftimos, MD @aftimosp.bsky.social · 13/02/2025

“Il faut imaginer une ploutocratie à l’échelle mondiale. […] La puissance croissante des technologies et de ceux qui les possèdent annonce une ère dystopique” www.lorientlejour.com/article/1447...

000